一、药品的基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，马应龙药业集团股份有限公司（以下简称"公司"或"本公司"）子公司江西马应龙美康药业有限公 司（以下简称"马应龙美康"）收到国家药品监督管理局核准签发的盐酸奥洛他定滴眼液（以下简称"该 药品"）《药品注册证书》（证书编号：2025S02553），现就相关情况公告如下： 药品名称：盐酸奥洛他定滴眼液 剂型：眼用制剂 规格：0.2%（2.5ml：5mg，按C21H23NO3计） 注册分类：化学药品4类 药品注册标准编号：YBH20042025 处方药/非处方药：处方药 上市许可持有人：江西马应龙美康药业有限公司 三、对公司的影响及风险提示 此次该药品获批《药品注册证书》有助于进一步丰富公司眼科产品线。由于药品生产、销售受医药行业 政策、市场竞争状况等因素影响存在不确定性，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告。 马应龙药业集团股份有限公司董事会 生产企业：浙江尖峰药业有限公司 药品批准文号：国药准字H20255181 药品批准文号有效期：至203 ...

Group 1 - The company plans to distribute a cash dividend of 10 yuan per 10 shares and a capital reserve conversion of 4 shares for every 10 shares at the end of 2024, totaling a dividend payout of 175 million yuan [1] - The total dividend distribution for 2024, including the mid-year payout of 87.21 million yuan, amounts to 262 million yuan, representing 77.64% of the net profit attributable to shareholders [1] - The company has conducted a total of 9 year-end dividends and 4 mid-year dividends since its listing in 2016, with a cumulative dividend amount of 999.5 million yuan and an average dividend rate of 81.82% [5] Group 2 - The company specializes in the field of ophthalmic drugs, with 60 approved ophthalmic drug numbers, of which 38 are included in the medical insurance catalog and 6 in the national essential drug catalog [4] - In 2024, the company achieved significant growth, with operating revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, a year-on-year increase of 40.84% [4] - The company’s net cash flow from operating activities reached 417 million yuan, reflecting a year-on-year growth of 31.31% [4]

Core Viewpoint - China Resources Double Crane (华润双鹤) has received approval for two significant pharmaceutical products, indicating potential growth in its product portfolio and market presence [1] Group 1: Product Approvals - The wholly-owned subsidiary, China Resources Zizhu Pharmaceutical Co., Ltd., received a drug supplement approval notice for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration (NMPA) [1] - The approval notice numbers are 2025B01154 and 2025B01155, highlighting the regulatory progress for the product [1] - The eye drops are intended for treating the signs and symptoms of allergic conjunctivitis, developed in collaboration with Nanjing Hengdao Pharmaceutical Technology Co., Ltd. [1] Group 2: Raw Material Approval - The controlling subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd., received a marketing approval notice for Fenofibrate Choline Raw Material from the NMPA [1] - The approval notice number is 2025YS00306, indicating successful regulatory compliance for the raw material [1] - Fenofibrate is used to lower triglyceride levels in patients with severe hypertriglyceridemia and for treating primary hypercholesterolemia or mixed dyslipidemia [1]